Pharma – Share Talk

Hemogenyx Pharma Plc (AIM:HEMO) HEMO-CAR-T 3rd Process Qualification Run Completed

Abm January 23, 2023

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its third Process Qualification (“PQ”) run of

Avacta Group PLC (AIM:AVCT) Successful Completion of Fourth Dose Escalation

Abm January 17, 2023

Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Hemogenyx Pharma Plc (LON:HEMO) Single CBR Can Treat Multiple Viruses

Abm January 9, 2023

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor (“CBR”) platform technology, designed to program immune cells to

Avacta Group PLC (AIM:AVCT) Avacta to Present at Theranostics FAP Summit

Abm October 31, 2022

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms.

Avacta Group PLC (AIM:AVCT) Proposed acquisition of Launch Diagnostics

Abm October 18, 2022

Launch Diagnostics is a leading independent distributor in the UK in-vitro diagnostics (IVD) market

Avacta Group PLC (AIM:AVCT) Phase I study of AVA6000 advances to fourth cohort

Abm September 1, 2022

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms.

Hemogenyx Pharma Plc Update With The Appointment of Medical Director

Abm August 10, 2022

One of America’s Top Bone Marrow Transplant and Oncology Doctors Joins Hemogenyx Pharmaceuticals as Medical Director

Avacta Group PLC (AIM:AVCT) Second dose escalation in phase 1 trial of AVA6000

Abm June 29, 2022

Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin

Avacta Group PLC (AIM:AVCT) Posting of Annual Report and Notice of AGM

Abm May 31, 2022

Avacta Group plc (AIM: AVCT), a clinical-stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms.